Too Early To Say FDA Issues Are Behind Lupin: Abhishek Singhal

PUBLISHED ON: July 8, 2016 | Duration: 10 min, 11 sec

   
loading..
Abhishek Singhal, associate director at Macquarie Capital Securities, says it is too early to come to a conclusion that all the FDA issues are behind Lupin. But he maintains that July 2015 inspection is all-clear is definitely a better situation for Lupin to be in rather than the entire 18 observations outstanding.
ALSO WATCH
Why SV Prasad Likes Pharma, Commodity Stocks

................................ Advertisement ................................

................................ Advertisement ................................

................................ Advertisement ................................

................................ Advertisement ................................